#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	12958	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2133	604.3	1	SNP	n	C1184T	0	.	.	1184	1184	C	1408	1408	C	783	C,G	729,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23482	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3637	644.2	0	.	n	.	0	T695C	SNP	695	695	T	1025	1025	C	711	C	665	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23482	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3637	644.2	0	.	n	.	0	G1337A	SNP	1337	1337	G	1667	1667	A	780	A,G	737,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23482	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3637	644.2	0	.	n	.	0	T1971C	SNP	1971	1971	T	2301	2301	C	729	C	669	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23482	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3637	644.2	1	SNP	n	A2045G	0	.	.	2045	2045	A	2375	2375	A	780	A	735	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23482	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3637	644.2	1	SNP	n	C2597T	0	.	.	2597	2597	C	2927	2927	C	711	C,T	669,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	1724	folP	852	852	100.0	folP.l6.c4.ctg.1	1486	115.4	1	SNP	p	R228S	1	.	.	682	684	AGC	1024	1026	AGC	156;157;156	A;G;C	153;153;153	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4498	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3319	135.2	1	SNP	p	S91F	0	.	.	271	273	TCC	544	546	TCC	163;162;164	T;C;C	152;151;153	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4498	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3319	135.2	1	SNP	p	D95G	0	.	.	283	285	GAC	556	558	GAC	165;165;163	G;A;C	155;153;152	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4498	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3319	135.2	1	SNP	p	D95N	0	.	.	283	285	GAC	556	558	GAC	165;165;163	G;A;C	155;153;152	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	1482	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1337	110.3	0	.	p	.	0	A39T	NONSYN	115	117	GCC	413	415	ACC	165;163;162	A;C;C	156;156;156	.	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	1482	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1337	110.3	0	.	p	.	0	R44H	NONSYN	130	132	CGC	428	430	CAC	161;161;161	C;A,G;C	152;151,1;153	.	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	1482	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1337	110.3	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	611	613	CAC	190;189;188	C;A;C	178;174;175	.	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	1482	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1337	110.3	1	SNP	p	G45D	0	.	.	133	135	GGC	431	433	GGC	162;163;164	G;G;C	153;154;155	mtrR.WHO_Y_01506:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	796	mtrR_promoter	250	250	100.0	mtrR_promoter.l6.c4.ctg.1	1004	79.1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4836	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2935	164.3	1	SNP	p	D86N	0	.	.	256	258	GAC	563	565	GAC	212;210;208	G;A;C	201;200;198	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4836	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2935	164.3	1	SNP	p	S87W	0	.	.	259	261	AGT	566	568	AGT	212;213;212	A;G;T	202;203;201	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4836	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2935	164.3	1	SNP	p	S87I	0	.	.	259	261	AGT	566	568	AGT	212;213;212	A;G;T	202;203;201	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4836	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2935	164.3	1	SNP	p	S87R	0	.	.	259	261	AGT	566	568	AGT	212;213;212	A;G;T	202;203;201	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4836	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2935	164.3	1	SNP	p	S88P	0	.	.	262	264	TCC	569	571	TCC	212;217;217	T;C;C	201;205;205	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	3780	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2688	140.1	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1509	1511	GGC	187;183;182	G;G;C,T	179;173;172,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	3556	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2347	150.8	1	SNP	p	A311V	0	.	.	931	933	GCA	1247	1249	GCA	180;179;180	G;C;A	165;163;166	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3556	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2347	150.8	1	SNP	p	I312M	0	.	.	934	936	ATC	1250	1252	ATC	185;185;184	A;T;C	171;172;168	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3556	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2347	150.8	1	SNP	p	V316P	0	.	.	946	948	GTG	1262	1264	GTG	176;175;174	G;T;G	164;162;161	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3556	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2347	150.8	1	SNP	p	V316T	0	.	.	946	948	GTG	1262	1264	GTG	176;175;174	G;T;G	164;162;161	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3556	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2347	150.8	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1766	1768	ACC	182;181;185	A;C;C	174;173;176	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3556	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2347	150.8	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1820	1822	GCG	159;159;158	G;C;G	140;126;132	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3556	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2347	150.8	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1820	1822	GCG	159;159;158	G;C;G	140;126;132	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3556	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2347	150.8	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1943	1945	GGC	170;171;170	G;G;C,T	154;154;151,1	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3556	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2347	150.8	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1952	1954	GGC	162;161;162	G,A;G;C	137,1;139;139	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3556	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2347	150.8	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1970	1972	CCG	135;140;139	C,G;CG,CGG;G	95,2;91,1;96	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	4754	ponA	2397	2397	99.96	ponA.l6.c30.ctg.1	3055	155.1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2054	porA	1146	1146	99.83	porA.l15.c4.ctg.1	1857	110.3	0	.	p	.	0	M83fs	FSHIFT	247	247	A	583	583	C	142	C	130	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2464	porB1b	1038	1038	99.52	porB1b.l15.c4.ctg.1	1564	156.8	0	.	p	.	0	I45V	NONSYN	133	135	ATT	456	458	GTT	192;194;192	G;T;T	184;185;183	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2464	porB1b	1038	1038	99.52	porB1b.l15.c4.ctg.1	1564	156.8	0	.	p	.	0	I75V	NONSYN	223	225	ATT	546	548	GTT	208;209;207	G;T;T	195;189;196	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2464	porB1b	1038	1038	99.52	porB1b.l15.c4.ctg.1	1564	156.8	0	.	p	.	0	S89T	NONSYN	265	267	AGC	588	590	ACC	205;209;210	A;C;C	183;190;190	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2464	porB1b	1038	1038	99.52	porB1b.l15.c4.ctg.1	1564	156.8	0	.	p	.	0	I98V	NONSYN	292	294	ATC	615	617	GTC	213;214;216	G;T;C	199;197;197	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2464	porB1b	1038	1038	99.52	porB1b.l15.c4.ctg.1	1564	156.8	1	SNP	p	G120K	1	.	.	358	360	AAG	681	683	AAG	208;205;204	A;A;G	190;189;187	porB1b.WHO_Y_02277c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2464	porB1b	1038	1038	99.52	porB1b.l15.c4.ctg.1	1564	156.8	1	SNP	p	A121N	1	.	.	361	363	AAC	684	686	AAC	202;200;201	A;A,G;C	188;185,1;185	porB1b.WHO_Y_02277c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2464	porB1b	1038	1038	99.52	porB1b.l15.c4.ctg.1	1564	156.8	1	SNP	p	N121D	0	.	.	361	363	AAC	684	686	AAC	202;200;201	A;A,G;C	188;185,1;185	porB1b.WHO_Y_02277c:1:1:N121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	8852	rpoB	4179	4179	100.0	rpoB.l6.c4.ctg.1	4835	182.6	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2012	2014	AAT	204;204;205	A;A;T	190;191;189	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	962	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	898	106.0	1	SNP	p	V57M	1	.	.	169	171	ATG	436	438	ATG	184;185;186	A;T;G	172;172;172	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
